Tarjei Widding-Havneraas

Tarjei Widding-Havneraas

Auto-generated profile, based on publicly available information

Tarjei Widding-Havneraas

Centre for Research and Education in Forensic Psychiatry, Haukeland University Hospital, Bergen, Norway

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2019 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Open access
PDF file
BBBeate Brinchmann
Beate Brinchmann
TWTarjei Widding‐Havneraas
Tarjei Widding‐Havneraas
MMMatthew Modini
Matthew Modini
MRMiles Rinaldi
Miles Rinaldi
CMCathrine F. Moe
Cathrine F. Moe
AMArnstein Mykletun
Arnstein Mykletun
Objective: Individual placement and support (IPS) has shown consistently better outcomes on competitive employment for patients with severe mental illness than traditional vocational rehabilitation. The evidence for efficacy originates from few countries, and generalization to different countries has been questioned. This has delayed implementation of IPS and led to requests for country‐specific RCTs. This meta‐analysis examines if evidence for IPS efficacy can be generalized between rather different countries.Methods: A systematic search was conducted according to PRISMA guidelines to identify RCTs. Overall efficacy was established by meta‐analysis. The generalizability of IPS efficacy between countries was analysed by random‐effects meta‐regression, employing country‐ and date‐specific contextual data obtained from the OECD and the World Bank.Results: The systematic review identified 27 RCTs. Employment rates are more than doubled in IPS compared with standard vocational rehabilitation (RR 2.07 95% CI 1.82–2.35). The efficacy of IPS was marginally moderated by strong legal protection against dismissals. It was not moderated by regulation of temporary employment, generosity of disability benefits, type of integration policies, GDP, unemployment rate or employment rate for those with low education.Conclusions: The evidence for efficacy of IPS is very strong. The efficacy of IPS can be generalized between countries.

17 November 2023 in European Psychiatry
Verified
Journal Article
Open access
PDF file
ACAshmita Chaulagain
Ashmita Chaulagain
ILIngvild Lyhmann
Ingvild Lyhmann
AHAnne Halmøy
Anne Halmøy
TWTarjei Widding-Havneraas
Tarjei Widding-Havneraas
ONOlav Nyttingnes
Olav Nyttingnes
AMArnstein Mykletun
Arnstein Mykletun
Background: There are now hundreds of systematic reviews on attention deficit hyperactivity disorder (ADHD) of variable quality. To help navigate this literature, we have reviewed systematic reviews on any topic on ADHD. Methods: We searched MEDLINE, PubMed, PsycINFO, Cochrane Library, and Web of Science and performed quality assessment according to the Joanna Briggs Institute Manual for Evidence Synthesis. A total of 231 systematic reviews and meta-analyses met the eligibility criteria. Results: The prevalence of ADHD was 7.2% for children and adolescents and 2.5% for adults, though with major uncertainty due to methodological variation in the existing literature. There is evidence for both biological and social risk factors for ADHD, but this evidence is mostly correlational rather than causal due to confounding and reverse causality. There is strong evidence for the efficacy of pharmacological treatment on symptom reduction in the short-term, particularly for stimulants. However, there is limited evidence for the efficacy of pharmacotherapy in mitigating adverse life trajectories such as educational attainment, employment, substance abuse, injuries, suicides, crime, and comorbid mental and somatic conditions. Pharmacotherapy is linked with side effects like disturbed sleep, reduced appetite, and increased blood pressure, but less is known about potential adverse effects after long-term use. Evidence of the efficacy of nonpharmacological treatments is mixed. Conclusions: Despite hundreds of systematic reviews on ADHD, key questions are still unanswered. Evidence gaps remain as to a more accurate prevalence of ADHD, whether documented risk factors are causal, the efficacy of nonpharmacological treatments on any outcomes, and pharmacotherapy in mitigating the adverse outcomes associated with ADHD.

7 July 2022 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
TWTarjei Widding-Havneraas
Tarjei Widding-Havneraas
HZHenrik Daae Zachrisson
Henrik Daae Zachrisson
Instrumental variables (IV) is a central strategy for identifying causal effects in absence of randomized experiments. Clinicians and epidemiologists may find the intuition of IV easy to grasp by comparison to randomized experiments. Randomization is an ideal IV because treatment is assigned randomly, and hence unaffected by everything else. IV methods in nonexperimental settings mimic a randomized experiment by using a source of "as good as" random variation in treatment instead. The main challenge with IV designs is to find IVs that are as good as randomization. Discovering potential IVs require substantive knowledge and an understanding of design principles. Moreover, IV methods recover causal effects for a subset of the population who take treatment when induced by the IV. Sometimes these estimates are informative, other times their relevance is questionable. We provide an introduction to IV methods in clinical epidemiology. First, we introduce the main principles and assumptions. Second, we present practical examples based on Mendelian randomization and provider preference and refer to other common IVs in health. Third, practical steps in IV analysis are presented. Fourth, the promise and perils of IV methods are discussed. Finally, we suggest further readings.

1 November 2021 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
TWTarjei Widding-Havneraas
Tarjei Widding-Havneraas
ACAshmita Chaulagain
Ashmita Chaulagain
ILIngvild Lyhmann
Ingvild Lyhmann
HZHenrik Daae Zachrisson
Henrik Daae Zachrisson
FEFelix Elwert
Felix Elwert
AMArnstein Mykletun
Arnstein Mykletun
Preference-based instrumental variables (PP IV) designs can identify causal effects when patients receive treatment due to variation in providers' treatment preference. We offer a systematic review and methodological assessment of PP IV applications in health research. We included studies that applied PP IV for evaluation of any treatment in any population in health research (PROSPERO: CRD42020165014). We searched within four databases (Medline, Web of Science, ScienceDirect, SpringerLink) and four journals (including full-text and title and abstract sources) between January 1, 1998, and March 5, 2020. We extracted data on areas of applications and methodology, including assumptions using Swanson and Hernan's (2013) guideline. We included 185 of 1087 identified studies. The use of PP IV has increased, being predominantly used for treatment effects in cancer, cardiovascular disease, and mental health. The most common PP IV was treatment variation at the facility-level, followed by physician- and regional-level. Only 12 percent of applications report the four main assumptions for PP IV. Selection on treatment may be a potential issue in 46 percent of studies. The assumptions of PP IV are not sufficiently reported in existing work. PP IV-studies should use reporting guidelines.

18 May 2022 in European Child & Adolescent Psychiatry
Verified
Journal Article
Open access
PDF file
TWTarjei Widding-Havneraas
Tarjei Widding-Havneraas
SMSimen Markussen
Simen Markussen
FEFelix Elwert
Felix Elwert
ILIngvild Lyhmann
Ingvild Lyhmann
IBIngvar Bjelland
Ingvar Bjelland
HZHenrik Daae Zachrisson
Henrik Daae Zachrisson
Rates of ADHD diagnosis vary across regions in many countries. However, no prior study has investigated how much within-country geographic variation in ADHD diagnoses is explained by variation in ADHD symptom levels. We examine whether ADHD symptom levels explain variation in ADHD diagnoses among children and adolescents using nationwide survey and register data in Norway. Geographical variation in incidence of ADHD diagnosis was measured using Norwegian registry data from the child and adolescent mental health services for 2011–2016. Geographical variation in ADHD symptom levels in clinics’ catchment areas was measured using data from the Norwegian mother, father and child cohort study for 2011–2016 (n = 39,850). Cross-sectional associations between ADHD symptom levels and the incidence of ADHD diagnoses were assessed with fractional response models. Geographical variation in ADHD diagnosis rates is much larger than what can be explained by geographical variation in ADHD symptoms levels. Treatment in the Norwegian child and adolescent mental health services is free, universally available upon referral, and practically without competition from the private sector. Factors beyond health care access and unequal symptom levels seem responsible for the geographical variation in ADHD diagnosis.

27 June 2023 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Open access
TWTarjei Widding-Havneraas
Tarjei Widding-Havneraas
HZHenrik Daae Zachrisson
Henrik Daae Zachrisson
SMSimen Markussen
Simen Markussen
FEFelix Elwert
Felix Elwert
ILIngvild Lyhmann
Ingvild Lyhmann
AMArnstein Mykletun
Arnstein Mykletun
Criminality rates are higher among persons with ADHD and evidence that medication reduces crime is limited. Medication rates between clinics vary widely even within universal healthcare systems, partly due to providers' treatment preferences. We used this variation to estimate causal effects of pharmacological treatment of ADHD on four-years criminal outcomes. We used Norwegian population-level registry data to identify all unique patients aged 10 to 18 diagnosed with ADHD between 2009 and 2011 (n=5,624), their use of ADHD medication, and subsequent criminal charges. An instrumental variable design, exploiting variation in provider preference for ADHD medication between clinics, was used to identify causal effects of ADHD medication on crime among patients on the margin of treatment, i.e., patients who receive treatment due to their provider's preference. Criminality was higher in patients with ADHD relative to the general population. Medication preference varied between clinics and strongly affected patients' treatment. Instrumental variable analyses supported a protective effect of pharmacological treatment on violence- and public-order-related charges with numbers needed to treat of 14 and 8, respectively. There was no evidence for effects on drug-, traffic-, sexual-, or property-related charges. This is the first study to demonstrate causal effects of pharmacological treatment of ADHD on some types of crimes in a population-based natural experiment. Pharmacological treatment of ADHD reduced crime related to impulsive-reactive behavior in patients with ADHD on the margin of treatment. No effects were found in crimes requiring criminal intent, conspiracy, and planning.